SELLAS Life Sciences Group, Inc. Profile Avatar - Palmy Investing

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunot…

Biotechnology
US, New York [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of SLS's Analysis
CIK: 1390478 CUSIP: 81642T209 ISIN: US81642T2096 LEI: - UEI: -
Secondary Listings
SLS has no secondary listings inside our databases.